4.33
+5.61%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Impact Biomedical
From its filings with the US Securities and Exchange Commission
Impact Biomedical is based in West Henrietta, New York and is incorporated in Nevada. Its shares trade on NYSE under the ticker IBO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $32,000 and a net loss of $11.8m. At that date it held total assets of $17.4m and shareholders' equity of $12.6m.
BioLife Science, Inc. We are the sole owner of the issued and outstanding common stock of Impact BioLife Science, Inc.
Biomedical, Inc. We own 90.9% of Global Biomedical, Inc. issued and outstanding common stock.
Sense, Inc. We own approximately 95.5% of the issued and outstanding common stock of Sweet Sense.
BioMedical has several unique and proprietary technologies that are in continuing development.
Company currently has two full-time employee and six shared employees with DSS as of December 31, 2025.
Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 16 Sept 2024
- Employees
- 1
- Website
- impactbiomedinc.com ↗
- Head office
- 275 WIREGRASS PKWY,, WEST HENRIETTA, NY, 14586
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Frank HeuszelChairman of the Board, Chief Executive Officer, since 2020$54,806
- Mr. Todd MackoChief Financial Officer$555
- Mr. Mark SuseckChief Operating Officer$158,689
- Mr. Heng Fai ChanDirector, since 2017
- Mr. Jason GradyDirector
- Dr. Elise BrownellIndependent Director$925
- Mr. Castel HibbertIndependent Director$2,175
- Mr. David KeeneIndependent Director$2,175
- Ms. Melissa SimsIndependent Director$2,175
- Mr. Christian ZimmermanIndependent Director$2,175
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Impact Biomedical Inc. is a wholly owned subsidiary of DSS, Inc. with strong intellectual property rights in bio health.
- Global BioLife, Inc. focuses on four key research areas including Linebacker and Equivir/Nemovir.
- The company's open-air defense initiatives target airborne diseases like tuberculosis and influenza.
Weaknesses
- Impact Biomedical Inc. employs only one full-time employee, limiting operational capacity.
- The company has a single listing date of 16 September 2024, indicating limited market presence.
- It operates solely in the US with no international expansion mentioned.
Opportunities
- The Linebacker project aims to develop a universal therapeutic drug platform for neurological diseases.
- Equivir/Nemovir offers antimicrobial medication using natural polyphenols for market growth.
- Laetose as a new sugar substitute presents a potential health food market opportunity.
Threats
- Global BioLife, Inc. faces competition in the bio health and biomedical fields without specified competitors.
- The open-air defense initiatives for airborne diseases may face regulatory challenges in the US.
- The company's reliance on DSS, Inc. as a parent company could create dependency risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.